The DRIPBaR is a growing IV therapy franchise concept that has shown impressive growth from 12 units in 2022 to 106 units by end of 2024. The investment ranges from $147K-$415K with a 7% royalty rate. Financial performance shows average sales of $393K annually. The franchise requires owner-operator involvement and offers protected territories with 3-mile radius protection. The business model focuses on intravenous vitamin therapy services under medical director supervision.
Generated from 2025 Franchise Disclosure Document
AI-generated from FDD analysis — use as a checklist with your attorney
Total startup costs, working capital, and financial requirements
Training, marketing support, technology, and operational assistance
Royalty, marketing, technology, and other ongoing fees
Revenue data, P&L estimates, and financial projections
Lawsuits, disputes, and legal risk assessment
Territory rights, term length, non-compete, and transfer rules
82 legal provisions scored on a franchisee-friendliness scale
Unit growth trends, exit rates, and system trajectory
Similar to The DRIPBaR in category and investment range